Here’s a preview of the featured content to watch for this week on Drug Topics®.
Coronavirus Research News
With an estimated 187 million COVID-19 vaccine doses administered and 558,000 COVID-19–associated deaths in the US as of this article’s press time, keeping up with pandemic news is more important than ever. Check back to Drug Topics® to stay informed on the latest coronavirus-related news and research.
The Latest from Total Pharmacy®: Assess and Manage Your Pharmacy’s Profitability
Examine the most essential financial key performance indicators for pharmacy businesses.
Optimize Pharmacy Technician Roles In Immuniation, Patient Care Services
During these unprecedented times, an optimized team workflow is crucial to each pharmacy’s success. On Wednesday, April 14, 2021, at 1:00 PM EDT, a webinar brought to you by Drug Topics® and the Pharmacy Technician Certification Board, will discuss how to optimize your pharmacy technicians.
Drug Topics® Journal, April 2021 Digital Edition
The April 2021 digital edition of Drug Topics Journal is now available on DrugTopics.com. In this issue, Drug Topics® covers the American Pharmacists Association 2021 Annual Meeting, and our cover story considers the importance of scaling up telepharmacy for the future.
Medical World News Updates
In an interview with Drug Topics®, Dr. Charles Lee, MD, senior director, clinical knowledge – Meducation at First Databank (FDB), will be discussing the recent Oregon law, which is requiring pharmacies to print prescription labels in any of 14 languages, through the lens of his own experience as a first generation Korean immigrant and the changing demographics in the United States.
This Week on Total Pharmacy®
Check back to totalpharmacy.com for a topline guide to legal and regulatory considerations when buying a pharmacy. In this article, experts from Frier Levitt provide a legal checklist for new pharmacy owners.
In Case You Missed It: FDA Approves New ADHD Treatment for Pediatric Patients
The FDA has approved viloxazine extended-release capsules (Qelbree; Supernus Pharmaceuticals) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients ages 6 to 17 years.